Safety and outcomes of anlotinib based chemotherapy in primary squamous cell thyroid carcinoma
10.3760/cma.j.cn115807-20240710-00238
- VernacularTitle:安罗替尼联合化疗在甲状腺鳞状细胞癌中的临床获益和安全性分析
- Author:
Huayuan PAN
1
;
Jing WANG
;
Jian YUE
;
Jing LI
;
Lei HU
;
Lei YE
;
Shengying WANG
Author Information
1. 中国科学技术大学附属第一医院西区（安徽省肿瘤医院）超声医学科，合肥 230031
- Publication Type:Journal Article
- Keywords:
Primary Squamous Cell Thyroid Carcinoma;
Anlotinib;
Target therapy;
Thyroid
- From:
Chinese Journal of Endocrine Surgery
2024;18(6):830-834
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and safety profile of anlotinib-based chemotherapy as the primary treatment modality for PSTC.Methods:This study included patients with locally advanced or metastatic PSTC who had not received any prior anti-tumor treatments between Jan. 2018 and Jul. 2023 at the Department of Breast Surgery, First Affiliated Hospital of the University of Science and Technology of China. The enrolled patients were administered anlotinib at a dose of 12 mg every 1 to 14 days for a total duration of 21 days, across 2 to 6 cycles. The chemotherapy regimen comprised paclitaxel, capecitabine, or docetaxel in combination with carboplatin or capecitabine. The assessed endpoints included the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and disease-specific survival (DSS) .Results:Fourteen patients were recruited for the study. Among them, one patient achieved a CR, seven patients attained a PR, five patients exhibited SD, and one patient presented with PD. The highest recorded ORR was 57.1%, accompanied by a DCR of 64.3%. The median PFS was 3.7 months, and the median DSS was 7.8 months. Notably, approximately 71.4% of patients experienced adverse events (AEs). The majority of AEs were manageable, with only one patient requiring a dosage adjustment, and no patients discontinued medication due to AEs.Conclusions:Anlotinib-based chemotherapy, as the primary therapeutic approach, demonstrates safety and efficacy in managing patients diagnosed with PSTC.
